Trimetazidine as an extra therapy for aluminum phosphide poisoning
Official title: Exploration of Potential Pathways to Mitigate the Toxicity of Some Pesticides
Run by Ain Shams University · NCT07916922 · Data updated 2026-11-12
In this pilot trial, adults with acute aluminum phosphide poisoning receive standard care plus trimetazidine to see if it helps save lives and improve recovery.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo, Abbassia) |
| Status | Recruiting |
| Started | May 5, 2026 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT07916922 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–60 years with acute aluminum phosphide poisoning and a severity score of 2 or 3.
✕Probably not a fit
Patients outside the age range, with coexisting serious medical conditions, or with co-ingestions may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, controlled pilot study at Ain Shams University Hospitals to test whether adding trimetazidine to the standard treatment for aluminum phosphide poisoning improves outcomes. Participants aged 18 to 60 with confirmed acute poisoning are randomly assigned to receive either standard supportive care or standard care plus trimetazidine. The main goal is to see if mortality within seven days is reduced, with secondary measures including hemodynamic changes, hospital and ICU length of stay, and ventilator needs. The study is conducted under ethical approval with informed consent and follows a predefined protocol for safety and data collection.
Why it matters
Potential benefit: If successful, trimetazidine could become an adjunct therapy to improve survival and recovery in aluminum phosphide poisoning.
How similar studies have gone: Previous research on trimetazidine in pesticide-related toxicity is limited; this pilot trial explores a novel adjuvant approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with diagnosis of acute aluminum phosphide poisoning. * Poison severity score 2 or 3 . Exclusion Criteria: * Patients less than 18 years and more than 60 years. * Pregnant and lactating females. * Presence of medical diseases (e.g. renal, hepatic, cardiovascular, neurological diseases and chronic pancreatitis.) * Presence of co-ingestion of other drugs or agents. * Pre consultation treatment. * Patients with known hypersensitivity for any agents or drugs especially trimetazidine formulations
Where it's running
-
Ain shams university
Cairo, Abbassia, Egypt Recruiting
Study contacts
- Principal investigator: Entsar A Elnabet, PHD student — Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University
- Study coordinator: Sarah A Eweda, Associate professor
- Email: onlysms@med.asu.edu..eg
- Phone: 01151157622
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.